Related Experiment Videos
[Should subclinical hypothyroidism in older persons be treated?]
Wendy P J den Elzen1, Jan W A Smit, Simon P Mooijaart
1Leids Universitair Medisch Centrum, afd. Public Health en Eerstelijnsgeneeskunde, Leiden, the Netherlands.
Nederlands Tijdschrift Voor Geneeskunde
|December 11, 2012
Summary
Subclinical hypothyroidism frequently affects older adults, but treatment guidelines remain inconsistent. High-quality evidence from randomized controlled trials is needed to inform definitive treatment recommendations for this population.
Area of Science:
- Gerontology
- Endocrinology
- Internal Medicine
Context:
- Subclinical hypothyroidism is a prevalent endocrine condition in the elderly population.
- Current clinical guidelines offer inconsistent recommendations for managing subclinical hypothyroidism in older individuals.
- There is a notable lack of high-quality evidence, particularly from randomized controlled trials (RCTs), regarding the treatment of subclinical hypothyroidism in this demographic.
Purpose:
- To highlight the inconsistencies in clinical guidelines for treating subclinical hypothyroidism in older persons.
- To underscore the absence of robust evidence from randomized controlled trials (RCTs) on the efficacy and safety of treating subclinical hypothyroidism in the elderly.
- To emphasize the need for large-scale, randomized placebo-controlled trials to establish definitive treatment recommendations.
Summary:
- Subclinical hypothyroidism is common in older adults, yet treatment recommendations are not standardized.
- Existing clinical guidelines lack consistency, especially concerning the management of subclinical hypothyroidism in the elderly.
- Currently, there is insufficient high-quality evidence from randomized controlled trials (RCTs) to guide treatment decisions for subclinical hypothyroidism in older individuals.
Impact:
- Informs clinicians and researchers about the current evidence gap in treating subclinical hypothyroidism in older adults.
- Highlights the necessity for future research, specifically large randomized placebo-controlled trials, to address treatment uncertainties.
- Aims to guide the development of evidence-based clinical practice guidelines for subclinical hypothyroidism in the geriatric population.
Related Concept Videos
01:23Hypothyroidism II: Pathophysiology
Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
01:25Hyperthyroidism I: Introduction
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:28Graves' Disease I: Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...